Literature DB >> 25589366

Thrombophilic state in young patients with acute myocardial infarction.

Elad Maor1, Paul Fefer, David Varon, Nurit Rosenberg, Nitza Levi, Hanoch Hod, Shlomi Matetzky.   

Abstract

The prevalence of thrombophilia and dyslipidemia among young survivors of acute coronary syndrome has not been clearly defined. The purpose of the current study was to investigate the prevalence of multiple markers of thrombophilia and dyslipidemia in a cohort of consecutive young survivors of acute coronary syndrome. The study cohort included 156 consecutive young patients (men <45 and women <50 years), admitted to the intensive cardiac care unit with newly diagnosed acute coronary syndrome. Analysis included baseline, clinical and epidemiological characteristics, angiographic coronary anatomy, echocardiographic evaluation, extensive lipid and thrombophilia laboratory profiles, and in-hospital and 1-year clinical outcomes for all patients. Acute myocardial infarction was diagnosed in 142 (92 %) patients, of whom 108 (72 %) had ST-segment elevation. Eighteen (12 %) patients had no traditional risk factors. Low levels of high-density lipoprotein (<40 mg/dL) were found in 101 (65 %) patients, and 49 (34 %) patients had elevated levels of lipoprotein(a) (Lp(a)) (>30 mg/dL). Eighteen (12 %) patients were diagnosed with antiphospholipid antibody syndrome (APS), and 73 (47 %) had at least one laboratory finding consistent with thrombophilia. Patients with APS had significantly higher levels of Lp(a) (46 ± 32 vs. 29 ± 31 mg/dL, p = 0.005). APS is a common prothrombotic state found in young survivors of acute coronary syndrome. Lp(a) levels are elevated among APS patients who present with premature acute coronary syndrome.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589366     DOI: 10.1007/s11239-014-1166-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  34 in total

Review 1.  Antiphospholipid antibodies and myocardial infarction.

Authors:  O Vaarala
Journal:  Lupus       Date:  1998       Impact factor: 2.911

2.  Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study.

Authors:  E Zuckerman; E Toubi; A Shiran; E Sabo; Z Shmuel; T D Golan; E Abinader; D Yeshurun
Journal:  Am J Med       Date:  1996-10       Impact factor: 4.965

3.  CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells.

Authors:  N S Haque; X Zhang; D L French; J Li; M Poon; J T Fallon; B R Gabel; M B Taubman; M Koschinsky; P C Harpel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

4.  Acute myocardial infarction in the young--The University of Michigan experience.

Authors:  Michele Doughty; Raj Mehta; David Bruckman; Sugata Das; Dean Karavite; Thomas Tsai; Kim Eagle
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

5.  Lipoprotein(a) in the arterial wall.

Authors:  U Beisiegel; A Niendorf; K Wolf; T Reblin; M Rath
Journal:  Eur Heart J       Date:  1990-08       Impact factor: 29.983

6.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

8.  Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins.

Authors:  G M Fless; C A Rolih; A M Scanu
Journal:  J Biol Chem       Date:  1984-09-25       Impact factor: 5.157

9.  Genetic susceptibility to death from coronary heart disease in a study of twins.

Authors:  M E Marenberg; N Risch; L F Berkman; B Floderus; U de Faire
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

10.  Antiphospholipid antibodies in acute coronary syndrome.

Authors:  K Veres; G Lakos; A Kerényi; Z Szekanecz; G Szegedi; Y Shoenfeld; P Soltész
Journal:  Lupus       Date:  2004       Impact factor: 2.911

View more
  4 in total

1.  Prothrombotic genetic risk factors in patients with very early ST-segment elevation myocardial infarction.

Authors:  Loukianos S Rallidis; Argyri Gialeraki; Georgios Tsirebolos; Stylianos Tsalavoutas; Maria Rallidi; Efstathios Iliodromitis
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

Review 2.  Mechanisms of Coronary Ischemia in Women.

Authors:  Jingwen Huang; Sonali Kumar; Olga Toleva; Puja K Mehta
Journal:  Curr Cardiol Rep       Date:  2022-07-29       Impact factor: 3.955

3.  Hypertension Is an Independent Predictor of Multivessel Coronary Artery Disease in Young Adults with Acute Coronary Syndrome.

Authors:  Junhua Ge; Jian Li; Haichu Yu; Bo Hou
Journal:  Int J Hypertens       Date:  2018-11-13       Impact factor: 2.420

4.  Intravascular Images of Coronary Stenosis with Multiple Channels in a Patient with Antiphospholipid Syndrome: The Optical Coherence Tomography Findings.

Authors:  Shigenori Ito; Takahiro Hasuo
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.